Biologics License Application submitted to FDA for idecabtagene vicleucel (Ide-cel, bb2121) for treatment of adults with relapsed and refractory multiple myeloma

The submission for this B-cell maturation antigen directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapy is based on open-label, single-arm, phase 2 KarMMa study (n=140) evaluating overall response rate.


Biospace Inc.